Search

Displaying results 961 - 970 of 2817 in total
  1. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  2. Drug

    Navafenterol

    go.drugbank.com/drugs/DB19195
    Investigational

    Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

  3. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma . It is transported across the m...

    Mixtures: Virt-Pn, Virt-PN
  4. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.

  5. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    The clinical applications of rose bengal as injectable formulation under the name PV-10 in melanoma, breast cancer and skin conditions such as eczema and psoriasis are being investigated in clinical trials

  6. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

  7. Drug

    Onion

    go.drugbank.com/drugs/DB10548
    Approved

    Onion allergenic extract is used in allergenic testing.

    Mixtures: Contractubex Gel, CONTRACTUBEX ® GEL
  8. Drug

    ATB-346

    go.drugbank.com/drugs/DB15377
    Investigational

    ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).

  9. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical an...